Unlocking New Opportunities to Improve Brain Health
By advancing a pipeline of innovative drug candidates and digital medicine tools
MindMed Clinical Trials
We are researching and developing a broad range of compounds, with the goal of unlocking new pathways for patients to experience sustained mental healing.
CLINICAL TRIALS
PRE-DISCOVERY
DISCOVERY
PRE-CLINICAL
PHASE 1A
PHASE 2A
PHASE 2B
PHASE 3
MINDMED DEVELOP (Commercial Drug Development Programs)
18-MC
Opioid Withdrawal
Opioid Withdrawal
PHASE 2A
LSD Microdosing
Adult ADHD
Adult ADHD
PHASE 2A
MINDMED DISCOVER (R&D Collaborations)
University Hospital Basel
LSD Assisted Therapy
Cluster Headaches
Multiple Ongoing or Completed: on LSD, MDMA, DMT, Psilocybin
LSD Assisted Therapy
PHASE 2
Cluster Headaches
PHASE 2
Multiple Ongoing or Completed: on LSD, MDMA, DMT, Psilocybin
PHASE 1
Our Philosophy
Overcome
We focus on helping patients overcome rather than survive
We believe patients deserve better than to linger in symptom management forever. We help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.
Community
We’re building a community with high standards of efficacy and compassion
Effective mental healthcare requires a coordinated effort from therapists, drug developers, and patients. We need shared data to drive insights and better treatment, so we’re working to build that community through partnerships and programs. We hold ourselves and our partners to the highest standards of efficacy and compassion so that we can progress the industry — and patient outcomes — faster.
Toolset
We offer a complete toolset — not just a pill
We’re not just another pill to manage symptoms. We offer a toolset — from breakthrough medicines and technology to compassionate therapy— for patients and therapists that accounts for the entire, complex patient journey.
Experiential Therapies
Experiential therapies have a high enough dose of a psychedelic (e.g., LSD, psilocybin) to produce a hallucinogenic effect and are administered under the supervision and guidance of a medical professional.
Psychedelic-Inspired Medicines
Psychedelic Inspired Medicines are derived from psychedelics, yet have a zero to negligible hallucinogenic effect and can be prescribed by doctors and picked up at the pharmacy for at-home use.
Next-Gen R&D
Developing best-in-class mental health care means more than clinical testing. In addition to conducting trials for the compounds we’re bringing to market, we’re also focused on next-gen research & development, comprehensive treatment programs and integrated toolsets that empower therapists to focus on what they do best.
People
We have the right people for the right reasons
Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.
Carol Vallone
Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee
Andreas Krebs
Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee
David Gryska
Board Director, Chair of Audit Committee
Roger Crystal, MD
Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee
Robert Barrow
Chief Executive Officer and Board Director
Suzanne Bruhn, PhD
Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee
Schond Greenway, MBA
Chief Financial Officer
Miri Halperin Wernli, PhD
Executive President
Daniel Karlin, MD, MA
Chief Medical Officer
Mark Sullivan, JD
Chief Legal Officer and Corporate Secretary
Francois Lilienthal, MD, MBA
Chief Commercial Officer
Carrie Liao, CPA
Chief Accounting Officer
Bridget Walton, MS
VP, Global Regulatory Affairs
Robert Malenka, MD, PhD
Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University
Peter Bergethon, MD
Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.
Robert Dworkin, PhD
Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester
Maurizio Fava, MD
Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)
Carole Abel, MBA
VP, Programs and Portfolio Office (PPO)
Peter Mack, PhD
VP, Pharmaceutical Development
Rafael Muniz, MD
VP, Global Medical Affairs
Phong Duong, PharmD
VP, Global Market Access
Maria Oquendo, MD, PhD
Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania
Matthias Liechti, MD, PhD
Scientific Collaborator & Advisor
Kim PC Kuypers, PhD
Scientific Collaborator & Advisor
Peter Gasser, MD
Clinical Advisor
Here to Stay
We’re built for operational agility and a long-run business model
This is a rapidly evolving space; we’re committed to building a business that becomes a long-lasting institution in effective mental health treatment — not a flash-in-the-pan startup that’s here today and gone tomorrow.
Patients-first
We’re a new kind of pharma company
We believe that, as a society, we’re at the start of a paradigm shift in mental health. We want to lead the way in doing it right. That means we’re community-focused, honest, and transparent. Together we can improve our collective mental health.
MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”
MindMed named one of 36 startups that could change the world
